Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR | MarketsandMarkets™

This image opens in the lightbox

News provided by

MarketsandMarkets

05 Jun, 2025, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The global Oligonucleotide Synthesis Market, valued at US$8.9 billion in 2024 stood at US$10.5 billion in 2025 and is projected to advance at a resilient CAGR of 18.6% from 2025 to 2030, culminating in a forecasted valuation of US$24.7 billion by the end of the period. The oligonucleotide synthesis market is experiencing significant growth, driven by the increasing applications of synthesized oligonucleotides in therapeutics & diagnostics. This growth is supported by technological advancements and rising investments in life sciences research and synthetic biology. Additionally, the growing emphasis on precision and personalized medicine contributes to this expansion, creating new opportunities as key players increase their research and development investments in emerging economies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Browse in-depth TOC on "Oligonucleotide Synthesis Market"

568 - Tables
77 - Figures
455 - Pages

By product, the oligonucleotide-based drugs segment is categorized into antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, and other oligonucleotide-based drugs. In 2024, the ASOs or antisense oligonucleotide-based drugs segment accounted for the largest share of the market. ASOs are short, single-stranded nucleic acids that bind selectively to RNA targets. These have seen rapid clinical & commercial uptake owing to their versatility in modulating gene expression, treating rare genetic disorders, and addressing oncology targets. Regulatory approvals for landmark ASO therapies, such as Nusinersen for spinal muscular atrophy and Inotersen for hereditary ATTR amyloidosis, have driven both analyst & investor confidence, fueling expanded manufacturing capacity and robust R&D pipelines. The central importance of developing the oligonucleotide therapy scene is pronounced by high yields, reduced manufacturing complexity, and known delivery platforms, thus contributing to market uptake during the studied period.

By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth of the hospitals segment is attributed to the rising demand for oligonucleotide-based drugs for rare & neurological diseases, primarily owing to the increasing target patient population. The significant share of this segment reflects the key role of hospitals in delivering these advanced treatments. The rising prevalence of infectious & chronic diseases is expected to fuel the need for precise therapeutics such as oligonucleotide drugs, which are also crucial for applying personalized medicine approaches in hospitals.

By geography, in 2024, North America accounted for the largest share of the oligonucleotide synthesis market owing to its presence of strong regional players who have advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals granted with supportive regulatory frameworks implemented by the USFDA and Health Canada. Product commercialization and innovation are the primary growth catalysts for the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers for upscaling production are also expected to be growth drivers for this regional segment.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350

Some of the leading players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US), among others.

Danaher Corporation (US):

One of the key players in the oligonucleotide synthesis market is Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, along with its sister company, Cytiva. Together, they offer a variety of products, including pre-designed and custom oligonucleotide probes, primers, and therapeutic oligonucleotides, such as antisense oligonucleotides (ASOs). Additionally, the company supplies reagents, consumables, and equipment, including synthesizers for oligonucleotide synthesis. Geographically, the company operates in over 50 countries spanning North America, the Asia Pacific, Europe, the Middle East, and Africa. IDT and Cytiva have focused on organic growth strategies, emphasizing expansions and partnerships. For instance, in 2023, Integrated DNA Technologies opened a therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This state-of-the-art facility is designed to produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility includes eight ISO cleanrooms, purification suites, chemical distribution & storage areas, quality control laboratories, analytical spaces for product testing, and ancillary & office spaces. There are also shell spaces set aside for future expansion.

Thermo Fisher Scientific (US)

Thermo Fisher is one of the leading players in the oligonucleotide synthesis market in 2024. This significant share is due to a strong product portfolio, including custom & pre-designed primers, probes, DNA, RNA oligos, and reagents & consumables. The company undertakes various organic & inorganic strategies to strengthen its position in the market. For instance, in 2021, Thermo Fisher Scientific collaborated with the University of Sheffield to develop workflows to characterize and monitor complex oligonucleotide and mRNA products. The company also has a strong geographic presence and operates in over 50 countries across North America, Europe, the Asia Pacific, and Latin America.

Biogen (US)

Biogen is also a leading company in the oligonucleotide synthesis market. The recent FDA accelerated approval of QALSODY (Tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) in adults, along with the growing adoption of Spinzara, a blockbuster oligonucleotide-based drug the company has offered since 2016, supports its leading position in the market. The company operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is used to produce antisense oligonucleotide drugs like Spinzara and other candidates currently in development. It employs various strategies to strengthen its market presence, including expansions and collaborations. For instance, in February 2025, Biogen and Stoke Therapeutics, Inc. collaborated to develop & commercialize Zorevunersen, an investigational antisense oligonucleotide (ASO) for treating Dravet syndrome.

For more information, Inquire Now!

Related Reports:

Next Generation Sequencing Market

Synthetic Biology Market

Genomics Market

Molecular Diagnostics Market

Biomarkers Market  

Get access to the latest updates on Oligonucleotide Synthesis Companies and Oligonucleotide Synthesis Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Modal title

Also from this source

Security Screening Market worth $13.80 billion in 2030 - Exclusive Report by MarketsandMarkets™

Security Screening Market worth $13.80 billion in 2030 - Exclusive Report by MarketsandMarkets™

The global security screening market is anticipated to grow from USD 9.92 billion in 2025 to USD 13.80 billion in 2030, at a compound annual growth...

Smart Warehousing Market worth $46.42 billion by 2030- Exclusive Report by MarketsandMarkets™

Smart Warehousing Market worth $46.42 billion by 2030- Exclusive Report by MarketsandMarkets™

The Smart Warehousing Market is expected to significantly increase in size from USD 31.21 billion in 2025 to USD 46.42 billion by 2030, growing at a...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.